Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease

NCT04617847 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

27

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of efficacy

Conditions

Huntington Disease

Interventions

DRUG: WVE-120101

Sponsor

Wave Life Sciences Ltd.